Evidence rankings.

FDA-approved dual incretin agonist; published weight-loss phase-3 data (SURMOUNT).

Phase-2 metabolic data (TRIUMPH) and ongoing phase-3 trials place it just behind approved agonists.

FDA-approved glycemic/weight-management drug with replicated phase-3 efficacy and safety data.

FDA-approved dual incretin agonist; published weight-loss phase-3 data (SURMOUNT).

Phase-2 metabolic data (TRIUMPH) and ongoing phase-3 trials place it just behind approved agonists.

Robust rat-model data on tendon and GI-tract healing; no completed human RCTs at scale.

Cosmetic and tissue-remodeling human data spanning two decades; controlled-trial literature modest.

GH-axis engagement well-validated; combination data superior to either agent alone.

FDA-approved for visceral adipose reduction with extensive adult-endocrinology data.

FDA-approved (Vyleesi) for hypoactive sexual desire; mechanism well-characterized.

Approved as labor-inducing therapeutic; behavioral and prosocial research well-replicated.

Approved across multiple jurisdictions for immune modulation; thirty-year clinical history.

Robust rat-model data on tendon and GI-tract healing; no completed human RCTs at scale.

FDA-approved for visceral adipose reduction with extensive adult-endocrinology data.

FDA-approved (Vyleesi) for hypoactive sexual desire; mechanism well-characterized.

Approved as labor-inducing therapeutic; behavioral and prosocial research well-replicated.

Approved across multiple jurisdictions for immune modulation; thirty-year clinical history.

Preclinical actin-binding and migration data; clinical evidence still early.

Mechanism well-characterized via sirtuin biology; clinical longevity trials still enrolling.

Russian small-cohort telomerase data; mechanism well-replicated in vitro.

Mice and rodent AMPK/metabolic data; human studies pilot-stage.

Human pigmentation data well-replicated; clinical use largely off-label and regulated.

Mitochondrial-cardiolipin mechanism replicated; clinical phase-2 endpoints published.

Hypothalamic GnRH control well-validated; clinical reproductive-endocrine studies ongoing.

Russian anxioregulatory studies; limited Western RCT data.

Russian BDNF/NGF regulatory studies; no large-scale Western RCTs.

Slow-wave sleep pilot data mostly preclinical; mechanism plausible but landscape still thin.

Anti-inflammatory preclinical data; gut-barrier research still early stage.

Pulsatile GHRH analog data; widely used but head-to-head trials vs DAC variant lacking.

Selective ghrelin/GHS-R agonist with favorable endocrine profile in human pilot work.

Preclinical actin-binding and migration data; clinical evidence still early.

Mechanism well-characterized via sirtuin biology; clinical longevity trials still enrolling.

Russian small-cohort telomerase data; mechanism well-replicated in vitro.

Mice and rodent AMPK/metabolic data; human studies pilot-stage.

Human pigmentation data well-replicated; clinical use largely off-label and regulated.

Mitochondrial-cardiolipin mechanism replicated; clinical phase-2 endpoints published.

Hypothalamic GnRH control well-validated; clinical reproductive-endocrine studies ongoing.

Russian anxioregulatory studies; limited Western RCT data.

Russian BDNF/NGF regulatory studies; no large-scale Western RCTs.

Slow-wave sleep pilot data mostly preclinical; mechanism plausible but landscape still thin.

Anti-inflammatory preclinical data; gut-barrier research still early stage.

Pulsatile GHRH analog data; widely used but head-to-head trials vs DAC variant lacking.

Selective ghrelin/GHS-R agonist with favorable endocrine profile in human pilot work.

Catalogue entry pending formal evidence classification.

Catalogue entry pending formal evidence classification.

Catalogue entry pending formal evidence classification.

Catalogue entry pending formal evidence classification.

Catalogue entry pending formal evidence classification.